AptarGroup, Inc. ATR R3KPHARMA
Company Overview
AptarGroup, Inc. designs and manufactures drug delivery, consumer product dispensing, and active material science solutions and services for the pharmaceutical, fragrance, facial skincare, color cosmetics, personal care, home care, and food and beverage markets. The company operates through three segments: Pharma, Beauty, and Closures. It provides dispensing pumps used to dispense sprays, liquids, or lotions from non-pressurized containers; fine-mist pumps for pharmaceutical and fragrance applications; and lotion pumps for viscous formulations, as well as closures, such as dispensing and non-dispensing solutions that enable product delivery without removal of the cap and used across various consumer end markets. The company also offers aerosol valves used in pressurized containers and continuous spray and metered-dose valves for pharmaceutical, personal care, and household applications; elastomeric primary packaging components; active material science solutions; and digital health solutions. The company primarily sells its products and services in Asia, Europe, Latin America, and North America. AptarGroup, Inc. was incorporated in 1992 and is headquartered in Crystal Lake, Illinois.
Why Investors Should Care
Trades at a P/E of 22.4, below the sector median of 24.8.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $3.78B (+5.4% YoY); net profit $392.79M.
- Trailing 12 Months Year-on-year growth — revenue +6.3%, earnings -18.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 3.6%, profit CAGR 5.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 3.60% |
| 1 Year: | 6.30% |
Compounded Profit Growth
| 5 Years: | 5.68% |
| 1 Year: | -18.60% |
Stock Price Performance
| 1 Year: | -7.47% |
| 6 Months: | -6.34% |
| 3 Months: | +11.47% |
| 1 Month: | -8.18% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)27.65 · Oversold
P/E of 22.40 is below the sector median of 24.83 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ATR AptarGroup, Inc. R3KPHARMA | 124.34 | 22.40 | $7.91B | 1.54% | 12.26% | 13.46% | 3.60% | 5.68% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 744.46M | 742.66M | 701.28M | 671.33M | 721.55M | 699.30M | 759.15M | 749.33M | - | - | - | - | - | - | - | - | - | - | - | - | 887.30M | 966.01M | 961.13M | 962.74M | 982.87M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 550.89M | 598.99M | 598.05M | 624.51M | 630.96M | - |
| Gross Profit | 170.50M | 152.58M | 173.73M | 192.50M | 171.57M | 149.58M | 181.73M | 183.35M | 179.17M | 179.22M | 209.17M | 209.02M | 192.54M | 184.78M | 233.84M | 231.74M | 215.22M | 193.59M | 227.50M | 213.49M | 233.99M | 231.02M | - | - | - | - | - | - | - | - | - | - | - | - | 336.41M | 367.01M | 363.08M | 338.22M | 351.91M | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 220.92M | 221.04M | 223.99M | 227.90M | 243.33M | - |
| Operating Income | 88.06M | - | 69.23M | 93.61M | 82.33M | - | 78.02M | 85.38M | 80.92M | - | 87.96M | 80.94M | 61.11M | - | 97.09M | 109.86M | 90.25M | - | 88.46M | 70.48M | 99.04M | - | 92.59M | 84.40M | 82.92M | 97.71M | 101.17M | 95.19M | 83.94M | 116.56M | 119.32M | 112.08M | 126.01M | 138.30M | 115.49M | 145.97M | 139.09M | 110.32M | 108.58M | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 183.01M | 220.47M | 242.89M | 185.10M | 186.44M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 11.35M | 10.85M | 13.53M | 17.00M | 16.94M | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 106.02M | 139.71M | 154.13M | 91.52M | 93.77M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 27.35M | 27.98M | 26.30M | 17.25M | 21.00M | - |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 63.72M | - | 83.95M | 55.28M | 47.26M | 62.42M | 63.62M | 54.24M | 54.76M | 83.07M | 84.30M | 83.10M | 90.45M | 100.04M | 78.80M | 111.72M | 127.93M | 74.34M | 72.67M | - |
| Diluted EPS | 0.83 | 0.68 | 0.67 | 0.91 | 0.82 | 0.77 | 0.81 | 1.01 | 0.83 | 0.77 | 0.92 | 0.86 | 0.60 | 0.62 | 0.96 | 1.12 | 0.85 | 0.73 | 0.84 | 0.63 | 0.95 | 0.79 | 1.24 | 0.81 | 0.70 | 0.93 | 0.95 | 0.81 | 0.82 | 1.24 | 1.26 | 1.23 | 1.34 | 1.48 | - | 1.67 | 1.92 | 1.13 | 1.12 | 1.36 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.07B | 1.86B | 2.09B | 2.36B | 2.35B | 2.52B | 2.60B | 2.32B | 2.33B | 2.47B | 2.76B | 2.86B | 2.93B | 3.23B | 3.32B | 3.49B | 3.58B | 3.78B |
| Gross Profit | - | - | 568.54M | 636.85M | 606.83M | 666.15M | 695.65M | 679.85M | 687.38M | 723.46M | 795.51M | 874.39M | 906.01M | - | - | - | - | - |
| Operating Income | 234.17M | 198.38M | 268.01M | 287.10M | 258.91M | 284.57M | 306.42M | 324.14M | 313.69M | 323.49M | 286.27M | 371.69M | 339.50M | 347.35M | 379.27M | 404.02M | 496.50M | 501.04M |
| Net Income | 153.50M | 124.62M | 173.48M | 183.68M | 162.61M | 171.99M | 191.66M | 199.35M | 205.59M | 220.03M | 194.75M | 242.20M | 214.04M | 244.10M | 239.29M | 284.49M | 374.54M | 392.79M |
| Diluted EPS | 2.18 | 1.79 | 2.48 | 2.65 | 2.38 | 2.52 | 2.85 | 3.09 | 3.17 | 3.41 | 3.00 | 3.66 | 3.21 | 3.61 | 3.59 | 4.25 | 5.53 | 5.89 |
| R&D Expense | - | 50.20M | 51.40M | 67.00M | 65.40M | 71.80M | 76.20M | 67.10M | 66.20M | 68.20M | 75.30M | 82.80M | 92.50M | 99.80M | 93.50M | 92.80M | 96.10M | 105.10M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 1.96B | 2.03B | 2.16B | 2.32B | 2.50B | 2.44B | 2.44B | 2.61B | 3.14B | 3.38B | 3.56B | 3.99B | 4.14B | 4.20B | 4.45B | 4.43B | 5.25B |
| Total Equity | 1.12B | 1.13B | 1.25B | 1.28B | 1.29B | 1.38B | 1.48B | 1.10B | 1.15B | 1.17B | 1.31B | 1.42B | 1.57B | 1.85B | 1.97B | 2.05B | 2.31B | 2.47B | 2.67B |
| Cash & Equivalents | 313.74M | 192.07M | 332.96M | 376.43M | 377.62M | 229.75M | 309.86M | 399.76M | 489.90M | 466.29M | 712.64M | 261.82M | 241.97M | 300.14M | 122.92M | 141.73M | 223.64M | 223.84M | 402.42M |
| Current Liabilities | - | - | 417.31M | 423.32M | 518.85M | 455.32M | 542.82M | 604.74M | 411.89M | 542.96M | 527.75M | 689.17M | 683.27M | 780.33M | 982.49M | 917.18M | 1.25B | 1.07B | 1.17B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 270.21M | 293.59M | 261.71M | - | - | - | - | 323.76M | 325.30M | 324.73M | 313.63M | 514.46M | 570.15M | 363.44M | 478.62M | 575.24M | 643.41M | 570.00M |
| Investing Cash Flow | -225.54M | -151.06M | -121.00M | - | - | - | - | -176.23M | -300.50M | -224.80M | -735.46M | -336.27M | -451.98M | -457.24M | -295.64M | -324.46M | -396.72M | -331.43M |
| Financing Cash Flow | -151.62M | -13.19M | -79.59M | - | - | - | - | -32.31M | -29.71M | 114.79M | -14.87M | -197.13M | -73.72M | -81.52M | -162.10M | -171.55M | -225.34M | -77.47M |
| Capital Expenditure | -203.60M | -144.93M | -118.80M | -179.69M | -174.05M | -151.51M | -161.94M | -149.32M | -128.99M | -156.62M | -211.25M | -242.28M | -245.95M | -307.94M | -310.43M | -312.34M | -276.48M | -270.42M |
| Free Cash Flow | 66.61M | 148.66M | 142.91M | - | - | - | - | 174.44M | 196.31M | 168.10M | 102.38M | 272.18M | 324.20M | 55.51M | 168.19M | 262.90M | 366.93M | 299.58M |
| Share Buybacks | 57.57M | 29.97M | 86.47M | 102.59M | 79.79M | 118.81M | 340.52M | - | - | 120.54M | 3.90M | 86.50M | 0 | 78.15M | 92.13M | 47.55M | 68.64M | 365.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | 27.2% | 27.0% | 25.9% | 26.4% | 26.8% | 29.3% | 29.5% | 29.3% | 28.8% | 30.6% | 30.9% | - | - | - | - | - |
| Operating Margin % | 11.3% | 10.7% | 12.8% | 12.2% | 11.0% | 11.3% | 11.8% | 14.0% | 13.5% | 13.1% | 10.4% | 13.0% | 11.6% | 10.8% | 11.4% | 11.6% | 13.9% | 13.3% |
| Net Margin % | 7.4% | 6.7% | 8.3% | 7.8% | 6.9% | 6.8% | 7.4% | 8.6% | 8.8% | 8.9% | 7.0% | 8.5% | 7.3% | 7.6% | 7.2% | 8.2% | 10.5% | 10.4% |
| ROE % | 13.6% | 9.9% | 13.6% | 14.2% | 11.8% | 11.6% | 17.4% | 17.3% | 17.5% | 16.8% | 13.7% | 15.4% | 11.6% | 12.4% | 11.7% | 12.3% | 15.2% | 14.7% |
| ROCE % | - | 12.9% | 16.7% | 17.5% | 13.9% | 14.6% | 16.7% | 16.0% | 15.2% | 12.4% | 10.6% | 12.9% | 10.6% | 11.0% | 11.5% | 12.6% | 14.8% | 12.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 9.65% | 6.14M | $763.80M |
| 2 | State Farm Mutual Automobile Insurance Co | 7.46% | 4.74M | $590.41M |
| 3 | Vanguard Portfolio Management LLC | 5.72% | 3.64M | $452.80M |
| 4 | Morgan Stanley | 5.54% | 3.52M | $438.52M |
| 5 | Vanguard Capital Management LLC | 4.55% | 2.89M | $360.10M |
| 6 | State Street Corporation | 4.50% | 2.86M | $356.32M |
| 7 | Victory Capital Management Inc. | 4.02% | 2.55M | $317.89M |
| 8 | Geode Capital Management, LLC | 2.75% | 1.75M | $217.50M |
| 9 | Dimensional Fund Advisors LP | 2.74% | 1.74M | $216.69M |
| 10 | Neuberger Berman Group, LLC | 2.44% | 1.55M | $192.74M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ATR
Why (ATR) Price Action Is Critical for Tactical Trading - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxPMEphRGtFSmZhbHJnYUVYWjc1QUFGLWMwMHBRNHo1MVlPUm9OOFM4LWptd21jYldEWG1ORFZsdnY3NWVKdTJRakhtSFVPMzl4VmY2YUJCaTBxV0MzT1huSDdiOVNBYnFQVHdnS2JrSHdvMEdxdWI1ZVQxTHVJLUc3YzF1QnFoRWpHZDAxdW…
Aptargroup Stock Price Forecast. Should You Buy ATR? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiR0FVX3lxTFBPNDhKRWFnNmptTmJYQ1RNTDNvZ002SDdIN3d4UmN3TWVXZndyOENDamhvRnc2ZmxJNVBfY3U2QktkejRTMzM4?oc=5" target="_blank">Aptargroup Stock Price Forecast. Should You Buy ATR?</a> <fo…
AptarGroup, Inc. (ATR) Stock Analysis: A 33.54% Potential Upside Beckons Investors - directorstalkinterviews.com
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxQY2oyNlJuaWc0bFYwcGNaS2tIRXBrSTNJMERZb0xmVF82a002Uk1RaTJoN0xHR3dCOFVuaURFOVVfREpMcnBVeFJ1Y0V2V2RyaDdNYnE5R0lBUmEzdXVPZXY3M3owSE5waExZLUJkaWZuc21PMUZlNGJSTkstTnpFN0V3bDMxdHZmV3VfRm…
Insider Sale: Segment Pres. of $ATR Sells 325 Shares - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxOeUs1QTdCNDdPNlozSjJLd2VPOUVTRG9JZ3h4MTUyaWhwYkxUN0pWSU9oamV3ZFJaVmpNRzhZcWVHOUUyaFU5NXFneDlmOGpQZ1hDd3RsU0g0c1p2OXlKT0wyREtwX0ZOSENXdUhWOGxlZlQ0Ym5BbVcyTlIxUEFrMDA5SEozNVhKdHRxb0…
AptarGroup (ATR) Stock Could Be Below Fair Value Following Its 15% Fall - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxPeENKWU9zazBuOUxqY3RIcnhYalhPbXJrTHo0dy1YZFpfTTlCUF92WXZIQktid2c5RUtwNlBNeDR4cFNKVW9OZjR2Zl80Z1dUWm5EQnlJQW5KdGdnTkw3ZDZDTFJaZzZ2bG1CVzRnN3BGT09iTm5wMkx1UHRtQzdjM3ZEWGFGQlZNS1QyRV…
AptarGroup (NYSE: ATR) officer plans 765-share sale after $400K June trade - Stock Titan
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxNOFFpNXFNdnViZ3djUlBPZUU3VWVlWEVONE1TeEVZTWg0RmVFTW5icGJBbXB6eVU3SEV2N3ZfS2JXWE1qTUVBb3hCVUJmRDNScWhlT2ZiV1duclUtTmgydHdZY1REZG1XNVJ6S05sdmE4cS1HTFhQcEJpV2NYYzFPaGQ1eFJLeUJjYUl5Qn…
ATR — Frequently Asked Questions
What is the current share price of AptarGroup, Inc. (ATR)?
As of 2026-09-19 21:16 PDT, AptarGroup, Inc. (ATR) trades at $124.34 on NYSE. Its 52-week range is $111.55 to $144.64.
What is the market capitalisation of ATR?
AptarGroup, Inc. (ATR) has a market capitalisation of $7.91B on NYSE.
What is the P/E ratio of ATR?
ATR trades at a trailing price-to-earnings (P/E) ratio of 22.40. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.95.
Does ATR pay a dividend?
AptarGroup, Inc. (ATR) currently offers a dividend yield of 1.54%.
What is the return on equity (ROE) of ATR?
ATR has a return on equity (ROE) of 13.46%. Its return on capital employed (ROCE) is 12.26%.
Is ATR a good stock to buy?
This page provides a data-driven analysis of AptarGroup, Inc. (ATR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.